Ergotamine | CAS#113-15-5 | Natural Nsp15 inhibitor

MedKoo Cat#: 463612 | Name: Ergotamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ergotamine is a vasoconstrictor that acts as an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. This product is a controlled substance. It is not available.

Chemical Structure

Ergotamine

CAS#113-15-5 (free base)

Theoretical Analysis

MedKoo Cat#: 463612

Name: Ergotamine

CAS#: 113-15-5 (free base)

Chemical Formula: C33H35N5O5

Exact Mass: 581.2638

Molecular Weight: 581.67

Elemental Analysis: C, 68.14; H, 6.07; N, 12.04; O, 13.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

113-15-5 (free base) 379-79-3 (tartrate)

Synonym

Ergotamine; Gynergen; NSC 95090; NS- 95090; NSC95090;

IUPAC/Chemical Name

(6aR,9R)-N-((2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide

InChi Key

XCGSFFUVFURLIX-VFGNJEKYSA-N

InChi Code

InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1

SMILES Code

O=C([C@H](C=C12)CN(C)[C@]2([H])CC3=CNC4=C3C1=CC=C4)N[C@](C(N5[C@H]6CC7=CC=CC=C7)=O)(C)O[C@@]5(O)[C@]8([H])CCCN8C6=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 581.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Barage S, Karthic A, Bavi R, Desai N, Kumar R, Kumar V, Lee KW. Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS- COV2 using computational approach. J Biomol Struct Dyn. 2020 Nov 6:1-18. doi: 10.1080/07391102.2020.1841026. Epub ahead of print. PMID: 33155531; PMCID: PMC7651200. 2: Dung JKS, Duringer JM, Kaur N, Scott JC, Frost K, Walenta DL, Alderman S, Craig AM, Hamm P. Molecular and alkaloid characterization of Claviceps purpurea sensu lato from grass seed production areas of the U.S. Pacific Northwest. Phytopathology. 2020 Nov 3. doi: 10.1094/PHYTO-07-20-0289-R. Epub ahead of print. PMID: 33141647. 3: Adeniyi JN, Adeniyi AA, Moodley R, Nlooto M, Ngcobo M, Gomo E, Conradie J. Unravelling the drugability of MSI2 RNA recognition motif (RRM) protein and the prediction of their effective antileukemia inhibitors from traditional herb concoctions. J Biomol Struct Dyn. 2020 Nov 2:1-14. doi: 10.1080/07391102.2020.1840442. Epub ahead of print. PMID: 33131412. 4: Bai L, Li X, Ma X, Zhao R, Wu D. In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. Anticancer Res. 2020 Nov;40(11):6051-6062. doi: 10.21873/anticanres.14626. PMID: 33109543. 5: Mwihia EW, Lyche JL, Mbuthia PG, Ivanova L, Uhlig S, Gathumbi JK, Maina JG, Eshitera EE, Eriksen GS. Co-Occurrence and Levels of Mycotoxins in Fish Feeds in Kenya. Toxins (Basel). 2020 Sep 30;12(10):627. doi: 10.3390/toxins12100627. PMID: 33008105; PMCID: PMC7600487. 6: Urits I, Yilmaz M, Bahrun E, Merley C, Scoon L, Lassiter G, An D, Orhurhu V, Kaye AD, Viswanath O. Utilization of B12 for the treatment of chronic migraine. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):479-491. doi: 10.1016/j.bpa.2020.07.009. Epub 2020 Jul 20. PMID: 33004160. 7: Khalifa NR, Gibbon S, Völlm BA, Cheung NH, McCarthy L. Pharmacological interventions for antisocial personality disorder. Cochrane Database Syst Rev. 2020 Sep 3;9:CD007667. doi: 10.1002/14651858.CD007667.pub3. PMID: 32880105. 8: Platzbecker K, Timm FP, Ashina S, Houle TT, Eikermann M. Migraine treatment and the risk of postoperative, pain-related hospital readmissions in migraine patients. Cephalalgia. 2020 Dec;40(14):1622-1632. doi: 10.1177/0333102420949857. Epub 2020 Aug 24. PMID: 32838537. 9: Gurung AB, Ali MA, Lee J, Abul Farah M, Al-Anazi KM. In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors. Saudi J Biol Sci. 2020 Oct;27(10):2674-2682. doi: 10.1016/j.sjbs.2020.06.005. Epub 2020 Jun 10. PMID: 32837219; PMCID: PMC7286259. 10: Gul S, Ozcan O, Asar S, Okyar A, Barıs I, Kavakli IH. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. J Biomol Struct Dyn. 2020 Aug 5:1-20. doi: 10.1080/07391102.2020.1802346. Epub ahead of print. PMID: 32752938; PMCID: PMC7484590. 11: Kurbanov RD, Mirzarakhimova ST, Abdullaev TA, Tsoy IA. [The Effect of Bromocriptine on Clinical and Laboratory Parameters in Patients With Peripartum Cardiomyopathy]. Kardiologiia. 2020 Jul 7;60(6):984. Russian. doi: 10.18087/cardio.2020.6.n984. PMID: 32720617. 12: Reghukumar A, Benson R. Burning Pain in the Legs. N Engl J Med. 2020 Jul 23;383(4):e18. doi: 10.1056/NEJMicm1911089. PMID: 32706537. 13: Rahman MM, Saha T, Islam KJ, Suman RH, Biswas S, Rahat EU, Hossen MR, Islam R, Hossain MN, Mamun AA, Khan M, Ali MA, Halim MA. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment. J Biomol Struct Dyn. 2020 Jul 21:1-11. doi: 10.1080/07391102.2020.1794974. Epub ahead of print. PMID: 32692306; PMCID: PMC7441776. 14: Miyagi H, Asada H, Suzuki M, Takahashi Y, Yasunaga M, Suno C, Iwata S, Saito JI. The discovery of a new antibody for BRIL-fused GPCR structure determination. Sci Rep. 2020 Jul 15;10(1):11669. doi: 10.1038/s41598-020-68355-x. PMID: 32669569; PMCID: PMC7363855. 15: Qiao Z, Zhang H, Ji HF, Chen Q. Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease. Computation (Basel). 2020 Jun;8(2):53. doi: 10.3390/computation8020053. Epub 2020 May 31. PMID: 32661494; PMCID: PMC7357730. 16: Schummer C, Zandonella I, van Nieuwenhuyse A, Moris G. Epimerization of ergot alkaloids in feed. Heliyon. 2020 Jun 30;6(6):e04336. doi: 10.1016/j.heliyon.2020.e04336. PMID: 32637710; PMCID: PMC7330613. 17: Ngo M, Tadi P. Ergotamine/Caffeine. 2020 Jul 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32310413. 18: Fischer MA, Jan A. Medication-overuse Headache. 2020 Jun 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 30844177. 19: Patrick HS, Mitra A, Rosen T, Ananth CV, Schuster M. Pharmacologic intervention for the management of retained placenta: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol. 2020 Sep;223(3):447.e1-447.e19. doi: 10.1016/j.ajog.2020.06.044. Epub 2020 Jun 25. PMID: 32592695. 20: Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-39. PMID: 32555120.